Nestlé sees no threat to its huge coffee business from the rising popularity of weight-loss drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, chief executive Mark Schneider said.
Instead the executive sees opportunities for Nestlé to expand its health science business, providing protein bars, powders and drinks for people taking the drugs, known as GLP-1 agonists.
"To dispel the myths, we haven't seen evidence that GLP-1 patients have a reduced appetite for coffee," Schneider wrote in a post on LinkedIn.
Coffee is critical for Nestlé, the world's biggest food company, which includes Nescafé Nespresso capsule coffees among its brands.
The category makes up around 20% of the Swiss company's annual sales, which last year reached CHF 94.4 billion (€99.9 billion).
The popularity of the new drugs has prompted concerns in the consumer and retail industry over whether food and drink sales will be impacted.
The drugs, originally designed to treat type 2 diabetes, have been shown to reduce food cravings and cause the stomach to empty more slowly.
Patients taking the drugs could lose lean muscle mass, a situation which could be countered by increasing protein intake and exercise, Schneider said.
Nestlé was already seeing increasing demand for protein powders, bars and drinks, he said, while vitamin and nutritional supplements had potential.
"Within Nestlé Health Science alone, we already have more than CHF 1.5 billion (€1.6 billion) of revenue coming from products that provide nutritional benefits suitable to GLP-1 patients," Schneider said.
Although the business was mainly focussed on North America, where GLP-1 adoption was highest, Nestlé was examining a broader geographical rollout of its products, Schneider said.
New products would also be launched next year to exploit the trend, Schneider said, without giving details.